ArticleJournal of pathogens2015
An Additive Effect of Oral N-Acetyl Cysteine on Eradication of Helicobacter pylori.
Article in Journal of pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2019Pooled it
- Article
- Characterization of antibiotic resistance and biofilm formation in clinical Helicobacter pylori isolates from Ningxia, China.Scientific reports · 2025Article
- Review
- Liposomal Drug Delivery againstPharmaceutics · 2024Article
- [The Recurrence ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Review
- Comparison of the effect of clarithromycin triple therapy with or withoutTherapeutic advances in gastroenterology · 2020Article
- Helicobacter pylori recrudescence and its influencing factors.Journal of cellular and molecular medicine · 2019Review
- Article
- N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection.Journal of microbiology (Seoul, Korea) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Helicobacter pylori is highly adapted to the gastric environment where it lives within or beneath the gastric mucous layer. The aim of this study was to evaluate whether the addition of N-acetyl cysteine to the treatment regimen of H. pylori infection would affect eradication rates of the disease. Methods. A total of 79 H. pylori positive patients were randomized to two therapeutic groups. Both groups received a 14-day course of three-drug regimen including amoxicillin/clarithromycin/omeprazole. Experimental group (38 subjects) received NAC, and control group (41 subjects) received placebo, besides three-drug regimen. H. pylori eradication was evaluated by urea breath test at least 4 weeks after the cessation of therapy. Results. The rate of H. pylori eradication was 72.9% and 60.9% in experimental and control groups, respectively (P = 0.005). By logistic regression modeling, female gender (OR 3.68, 95% CI: 1.06-5.79; P = 0.040) and treatment including NAC (OR 1.88, 95% CI: 0.68-3.15; P = 0.021) were independent factors associated with H. pylori eradication. Conclusion. The results of the present study show that NAC has an additive effect on the eradication rates of H. pylori obtained with three-drug regimen and appears to be a promising means of eradicating H. pylori infection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.